SAB Biotherapeutics (SABS) Payables (2020 - 2026)
SAB Biotherapeutics' (SABS) quarterly Payables came in at $3.5 million in Q1 2026, up 33.32% YoY from $2.7 million in Q1 2025, and up 12.69% on a QoQ basis from $3.1 million in Q4 2025.
SAB Biotherapeutics (SABS) Payables (2020 - 2026) Analysis & Trends
SAB Biotherapeutics (SABS) has 7 years of Payables data on file, last reported at $3.5 million in Q1 2026.
- Quarterly Payables rose 33.32% year-over-year to $3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.5 million (up 33.32% YoY) and the FY2025 annual result came in at $3.1 million, up 59.64% from the prior year.
- Payables rose to $3.5 million in Q1 2026, from $3.1 million in the prior quarter.
- In the past five years, Payables ranged from a high of $6.0 million in Q1 2022 to a low of $1.3 million in Q3 2024.
- A 5-year average of $3.0 million and a median of $2.6 million in 2025 frame the typical range for Payables.
- Annual changes were most pronounced in 2023 — Payables sank 70.97% — and 2025, when it jumped 127.83%.
- Tracing SABS's Payables over 5 years: stood at $4.5 million in 2022, then plunged by 55.15% to $2.0 million in 2023, then decreased by 1.31% to $2.0 million in 2024, then surged by 59.64% to $3.1 million in 2025, then gained by 12.69% to $3.5 million in 2026.
- The last three Payables figures came in at $3.5 million (Q1 2026), $3.1 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | SAB Biotherapeutics | 308.92 Mn | 308.92 Mn | - | 3.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.86 Mn |
| Mar 31, 2026 | 3.54 Mn |
| Dec 31, 2025 | 3.15 Mn |
| Sep 30, 2025 | 2.95 Mn |
| Jun 30, 2025 | 2.62 Mn |
| Mar 31, 2025 | 2.66 Mn |
| Dec 31, 2024 | 1.97 Mn |
| Sep 30, 2024 | 1.30 Mn |
| Jun 30, 2024 | 1.79 Mn |
| Mar 31, 2024 | 2.08 Mn |
| Dec 31, 2023 | 2.00 Mn |
| Sep 30, 2023 | 1.62 Mn |
| Jun 30, 2023 | 1.52 Mn |
| Mar 31, 2023 | 1.89 Mn |
| Dec 31, 2022 | 4.45 Mn |
| Sep 30, 2022 | 5.51 Mn |
| Jun 30, 2022 | 5.22 Mn |
| Mar 31, 2022 | 6.02 Mn |
| Dec 31, 2021 | 6.26 Mn |
| Dec 31, 2020 | 7.92 Mn |